Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 2 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Hangzhou Zhongmei Huadong Pharmaceutical Co. Ltd. currently has 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 2 distinct examiners and 2 distinct art units. This indicates a focused prosecution effort with some overlap in the individuals reviewing the applications. The involvement of 2 distinct art units suggests that the applications cover different technical aspects of the company's pharmaceutical research, requiring specialized knowledge for each.
ANDERSON, REBECCA L is the busiest examiner for the portfolio, currently managing 2 pending office actions. With the 3 pending office actions distributed among a small group of examiners, ANDERSON, REBECCA L handles a larger share of the workload. This concentration means that her examination style and preferences will influence the portfolio's overall success. The involvement of the distinct art units further highlights the need for a strategy that addresses multiple technical groups.
For a practitioner, having 2 pending office actions with ANDERSON, REBECCA L means that building a consistent rapport with her is crucial. The distribution across the distinct art units requires staying informed about the practices of both groups. This combination of a primary examiner and multiple art units is an important factor in the prosecution strategy. Practitioners should carefully monitor how the pending office actions under the busiest examiner progress to identify any common themes.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
| No statute on record | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ANDERSON, REBECCA L | 2 | 73.3% | +23.7% |
| YOO, SUN JAE | 1 | 71.2% | +0.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18000099 | METHOD FOR PREPARING GLP-1 RECEPTOR AGONIST | YOO, SUN JAE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18000102 | PREPARATION METHOD FOR (S)-2-AMINO-3-(4-(2,3-DIMETHYLPYRIDIN-4-YL)PHENYL)METHYL PROPIONATE DIACID SALT | ANDERSON, REBECCA L | — |
| 18000108 | METHOD FOR PREPARING GLP-1 RECEPTOR AGONIST FREE BASE | ANDERSON, REBECCA L | — |
| Art Unit | Apps |
|---|---|
| 1626 | 2 |
| 1621 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18000102 | PREPARATION METHOD FOR (S)-2-AMINO-3-(4-(2,3-DIMETHYLPYRIDIN-4-YL)PHENYL)METHYL PROPIONATE DIACID SALT | ANDERSON, REBECCA L | 1626 | Other | Final Rejection | — | Pending | Jul 17, 2023 |
| 18000099 | METHOD FOR PREPARING GLP-1 RECEPTOR AGONIST | YOO, SUN JAE | 1621 | §102§112 | Non-Final OA | — | Pending | Jul 17, 2023 |
| 18000108 | METHOD FOR PREPARING GLP-1 RECEPTOR AGONIST FREE BASE | ANDERSON, REBECCA L | 1626 | §112 | Non-Final OA | — | Pending | Jul 17, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialHangzhou Zhongmei Huadong Pharmaceutical Co. Ltd. has 3 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Rebecca L Anderson has the most, with 2 of Hangzhou Zhongmei Huadong Pharmaceutical Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
